Christophe Moreno - Concepedia

Author

Christophe Moreno

Also Known As

C Castro, C Moreno, C. Moreno, Carmen Victoria Rojas Moreno, Christophe Moreno, Claudia Maria Moreno, Claudia María Moyano Moreno, E Vichinsky, Francisco Falabella, Leteurtre, Emmanuelle

397

Publications

22.5K

Citations

H-Index

124

Concepts

All Affiliations

Université Libre de Bruxelles Erasmus Hospital Inserm Assistance Publique – Hôpitaux de Paris Université Paris Cité

About

Christophe Moreno is an author at Université Libre de Bruxelles specializing in medicine, hepatology, and hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	59	6.6K
2	Health Sciences	15	16	2.2K
3	Public Health	5	6	571
4	Engineering	1	1	27
5	Natural Sciences	1	1	53

Christophe Moreno

133

Publications

15.6K

Citations

H-Index

Page 1

	Year	Citations
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection Jordan J. Feld, Ira M. Jacobson, Christophe Hézode, New England Journal of Medicine	2015	1.1K
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening Vlad Ratziu, Stephen A. Harrison, Sven Francque, Gastroenterology	2016	993
Early Liver Transplantation for Severe Alcoholic Hepatitis Philippe Mathurin, Christophe Moreno, Didier Samuel, New England Journal of Medicine	2011	933
ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV Péter Ferenci, David Bernstein, Jacob Lalezari, New England Journal of Medicine	2014	690
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH Sven Francque, Pierre Bédossa, Vlad Ratziu, New England Journal of Medicine	2021	655
A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis Stephan Buch, Felix Stickel, Eric Trépo, Nature Genetics Genome-wide Association StudyHepatologyMedicineLiver PhysiologyGenetics	2015	543
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm Homie Razavi, Imam Waked, Christoph Sarrazin, Journal of Viral Hepatitis	2014	484
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue, Journal of Hepatology FibrosisHepatologyLiver PhysiologyClinical TrialsPathology	2020	438
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment Edward Gane, Eric Lawitz, David Pugatch, New England Journal of Medicine	2017	394

Page 1